Good results for Sapacitabine (Estybon)
Hi All,
The researchers have presented info about the Phase II trial: http://www.equities.com/news/headlin...3314&cat=hcare Kind regards Birgitta-A |
The trial of sapacitabine was for int-2 or high risk MDS patients, age 60 and over, who had failed Vidaza or Dacogen. Sapacitabine appears to lengthen survival in these worst cases from the 4 to 6 month range to the 8 to 10 month range.
The trial studied three dosage schedules, finding that the best results were with 200 mg given twice daily for 7 days. Results weren't quite as good with 300 mg given once daily for 7 days or 100 mg given once daily for 5 days per week over 2 weeks. |
All times are GMT -4. The time now is 03:56 AM. |
Powered by vBulletin® Version 3.6.7
Copyright ©2000 - 2024, Jelsoft Enterprises Ltd.
Forum sites may contain non-authoritative and unverified information.
Medical decisions should be made in consultation with qualified medical professionals.
Site contents exclusive of member posts Copyright © 2006-2020 Marrowforums.org